Dr. Sulaiman Al Habib Medical Services Group announces its Annual Financial results for the period ending on 2024-12-31
| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 11,200.43 | 9,508.44 | 17.79 | ||
| Gross Profit (Loss) | 3,744.26 | 3,270.05 | 14.5 | ||
| Operational Profit (Loss) | 2,356.26 | 2,095.65 | 12.44 | ||
| Net profit (Loss) | 2,315.29 | 2,046.01 | 13.16 | ||
| Total Comprehensive Income | 2,331.16 | 2,041.79 | 14.17 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 7,175.14 | 6,485.48 | 10.63 | ||
| Profit (Loss) per Share | 6.62 | 5.85 | |||
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Revenues: for the year 2024, revenues grew by 17.79% reaching SAR 11,200.43 million, with an increase of SAR 1,691.99 million as compared to SAR 9,508.44 million for the previous year, as a result of the growth in revenue for all the group’s segments during the year 2024.
Revenue growth for the year 2024 was mainly driven by the growth in both hospital and pharmacy segments, due to the increase in the hospital segment’s number of patients, which has a positive correlation with the pharmacy segment sales increase, as compared to the previous year.
It’s worth to mention that the group announced the opening of Al-Fayhaa Hospital (Al-Fayhaa - Jeddah) and Shamal Al Riyadh Hospital (Al-Sahafa - Riyadh), where both projects are currently in the revenue ramp-up phase during their first operational year. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | EBITDA for the year 2024 increased by 17.58%, reaching SAR 2,975.43 million, maintaining EBITDA margin at 26.57% compared to 26.61% in the previous year.
Net Income for the year 2024 increased by 13.16% to reach SAR 2,315.29 million, net income margin reaching 20.67% versus 21.52% for the previous year. Net Income increase was mainly driven by the revenue growth due to the increase in the number of patients and inpatient occupancy. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | na |
| Reclassification of Comparison Items | na |
| Additional Information | na |
| Attached Documents |  |
Comments